論文

査読有り 国際誌
2020年3月17日

Nimustine Treatment of 11 Cases of Canine Histiocytic Sarcoma.

Journal of the American Animal Hospital Association
  • Hiroyuki Tani
  • ,
  • Sena Kurita
  • ,
  • Ryo Miyamoto
  • ,
  • Harumi Sawada
  • ,
  • Aki Fujiwara-Igarashi
  • ,
  • Masaki Michishita
  • ,
  • Daigo Azakami
  • ,
  • Daisuke Hasegawa
  • ,
  • Kyoichi Tamura
  • ,
  • Makoto Bonkobara

記述言語
英語
掲載種別
DOI
10.5326/JAAHA-MS-6959

The objective of this retrospective study was to report treatment outcomes in dogs with histiocytic sarcoma (HS) that were treated with nimustine (ACNU). This study evaluated data from 11 dogs including 5 with macroscopic tumors that were treated in the primary setting and 6 that underwent aggressive local therapy while being treated in the adjuvant setting. The median ACNU starting dose was 25 mg/m2 (range, 20-30 mg/m2; 3- to 5-wk intervals, 1-8 administrations). The median overall survival in the primary and adjuvant settings was 120 days (median progression-free survival [PFS], 63 days) and 400 days (median PFS, 212 days), respectively. Neutropenia was observed in eight cases (grade 1, n = 1; grade 2, n = 2; grade 3, n = 2; grade 4, n = 3) with nadir neutrophil count at 1 wk after ACNU administration. Mild gastrointestinal toxicity (grade 1-2) was observed in three cases. ACNU was well tolerated and showed a similar outcome to that seen for lomustine, which is a drug commonly used to treat canine HS, in terms of overall survival and PFS in the current study population. Further investigations will need to be undertaken to definitively determine if ACNU is an appropriate alternative to lomustine for the treatment of HS.

リンク情報
DOI
https://doi.org/10.5326/JAAHA-MS-6959
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32182105